Company intelligence / Profile preview

Semnur Pharmaceuticals, Inc.

Palo Alto, California, United Statessemnurpharma.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Semnur has completed a Phase 3 trial for SP-102 (SEMDEXA™), which met primary and important key secondary endpoints. The treatment decreased pain intensity for over a month in sciatica patients and resulted in statistically significant and clinically meaningful improvement in the disability index score while maintaining safety comparable to placebo[3].

Therapeutic areas: Neurology
Modalities: Injectable corticosteroid gel formulationNon-opioid pain therapies
Industry: Biotech

Drug pipeline

1 asset

dexamethasone sodium phosphate

Phase 3

Indications: Sciatica, Chronic radicular pain, Lumbosacral radicular pain

Partnerships

Denali Capital Acquisition Corp. (for SPAC merger)

Beyond the preview

Go deeper on Semnur Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Semnur Pharmaceuticals, Inc..

Explore the full profile